A recent study demonstrates marked regression of calcinosis in patients with hyperphosphatemic familial tumoral calcinosis following treatment with canakinumab. This finding highlights the potential of canakinumab as a therapeutic option for this rare condition.
marked regression of calcinosis with canakinumab in hyperphosphatemic familial tumoral calcinosis
Original title: “Marked regression of calcinosis with canakinumab in hyperphosphatemic familial tumoral calcinosis.”